Skip to content
Atlas Research Compounds

Healthy aging

Pinealon Review

A bounded review of Pinealon, EDR-related publications, short-peptide bioregulator context, and the limits of the verified record.

9 minute read

What the record supports

Pinealon is cataloged as EDR, a short tripeptide appearing in bioregulator and neural-aging literature.

The verified study set includes cell viability, prenatal hyperhomocysteinemia, aged-rat stress models, serotonin-expression work, and broader short-peptide publications.

What the record does not support

The current record does not justify collapsing Pinealon into a generalized anti-aging claim. Study model, publication group, replication status, and endpoint specificity remain central limitations.

Atlas therefore places Pinealon in healthy-aging and cognition hubs but keeps its evidence rating below compounds with mature human programs.

Sources and further reading

  1. 01

    Short peptide bioregulator literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source

Research map

Compound: PinealonCompound: CortagenCompound: SemaxStudy PMID 33396470: EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's DiseaseStudy PMID 21978084: Pinealon increases cell viability by suppression of free radical levels and activating proliferative processesStudy PMID 25051764: [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon].Topic hub: Healthy AgingTopic hub: CognitionTopic hub: Peptide ResearchComparison: Pinealon vs. CortagenComparison: Pinealon vs. Semax